RT Journal Article
SR Electronic
T1 Imaging papillary thyroid cancer brain metastases using FDG-PET/CT
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1070
OP 1070
VO 51
IS supplement 2
A1 Rini, Josephine
A1 Nguyen, Vinh
A1 Ben-Levi, Eran
A1 Naidich, Jason
A1 Li, Jian Yi
A1 Palestro, Christopher
YR 2010
UL http://jnm.snmjournals.org/content/51/supplement_2/1070.abstract
AB 1070 Learning Objectives 1. Recognize that brain metastases occur infrequently in patients with papillary thyroid carcinoma, but are not uncommon in patients with metastatic papillary thyroid carcinoma who develop new sites of disease. 2. Describe the appearance of papillary thyroid carcinoma brain metastases on FDG-PET/CT. 3. Discuss the value of FDG-PET for detecting brain metastases in general and the potential role it may play in detecting brain metastases from papillary thyroid carcinoma. The overall incidence of brain metastases from papillary thyroid cancer is low; however, the brain is a major site for subsequent metastases in patients with metastatic papillary thyroid carcinoma who develop new sites of disease. FDG-PET generally is not useful detecting brain metastases, which often are small and may be obscured by the high FDG uptake of normal cortical gray matter, and there are few data on its role in the detection of metastatic thyroid carcinoma to the brain. We present 2 cases in which brain metastases from papillary thyroid carcinoma were readily detected using FDG-PET/CT. Methods: (1) Retrospective data review. (2) Compare PET/CT scan findings in 2 patients with papillary thyroid carcinoma metastatic to the brain with correlative clinical data including but not limited to contemporaneous MRI scans, I-131 scans and brain biopsy results. Conclusion: Our study demonstrated high avidity of papillary thyroid carcinoma brain metastases for FDG and therefore, consideration should be given to including the entire brain in FDG-PET/CT studies performed on patients with papillary thyroid cancer